Drug Profile
Research programme: mucosal-penetrating therapeutics - KALA BIO
Alternative Names: MPPs - KALA BIO; Mucosal-Penetrating Products - KALA BIO; RTKi-MPP - KALA BIOLatest Information Update: 04 Aug 2023
Price :
$50
*
At a glance
- Originator Kala Pharmaceuticals
- Developer KALA BIO
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Receptor protein-tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetic macular oedema; Female genital diseases; Gastrointestinal disorders; Pseudomonal infections; Respiratory tract disorders; Retinal disorders; Retinal vein occlusion; Wet age-related macular degeneration